1
|
Masuka JT. An Exploratory Bibliometric Analysis of African Pharmacovigilance Research Output Using SCOPUS. Cureus 2024; 16:e56295. [PMID: 38629007 PMCID: PMC11018517 DOI: 10.7759/cureus.56295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/16/2024] [Indexed: 04/19/2024] Open
Abstract
Most global pharmacovigilance (PV) data is derived from developed countries. However, the determinants of the differences in PV research output between developing and developed countries contributing to this discrepancy still need to be explored. The objective of the current study is to describe the publication trends and characteristics of pharmacovigilance-related research stemming out of Africa in comparison to that emanating from developed countries. A bibliometric analysis was carried out using the SCOPUS literature index for published global pharmacovigilance-related articles or documents pre-COVID-19. Data on annual publication trends, citations, author affiliations, and other study characteristics such as study funding were extracted and descriptively analyzed. Author co-citation and keyword co-occurrence analyses were also conducted and presented using VOSviewer software program version 1.6.15 (CWTS, Universiteit Leiden, Netherlands). During the period under review, a total of 27,516 documents were retrieved globally. Out of these, 588 (2.1 %), 9,438 (34.3 %), and 17,829 (64.8 %) were from Africa, Europe, and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) founder member countries respectively. Annual publications have steadily increased, but at a slower rate in Africa compared to Europe. The mean annual publications and number of citations are significantly lower in Africa compared to Europe, p < 0.0001 for both parameters. The top 10 funders of African PV activities are European and American organizations. In conclusion, improved PV activity driven by international funders has been notable on the African continent. However, there is an increased need for local funding, government involvement, and legislation to improve PV activities on the African continent.
Collapse
Affiliation(s)
- Josiah T Masuka
- Dermatology, Faculty of Health Sciences, University of Zimbabwe, Harare, ZWE
| |
Collapse
|
2
|
Elhawary MA, Ogar CK, Tarapués M, Caro A, Ndagije HB, Benabdallah G, Sefiani H, Rostom H. The Role of ISoP in the Advancement of Pharmacovigilance in Low-and Middle-Income Countries (LMICs). Drug Saf 2023; 46:1307-1312. [PMID: 37874450 DOI: 10.1007/s40264-023-01363-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/05/2023] [Indexed: 10/25/2023]
Affiliation(s)
- Mohamed A Elhawary
- Egyptian Ministry of Health and Population, Central Administration for Pharmaceutical Affairs (Research Coordinator of ISoP Egypt Chapter in His Personal Capacity), Cairo, Egypt.
- International Society of Pharmacovigilance (ISoP) Egypt Chapter, Cairo, Egypt.
| | - Comfort K Ogar
- International Society of Pharmacovigilance (ISoP) Africa Chapter, Abuja, Nigeria
- Utrecht Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University (General Secretary of ISoP Africa Chapter), Utrecht, The Netherlands
| | - Mónica Tarapués
- International Society of Pharmacovigilance, ISoP Secretariat Ltd, London, UK
- International Society of Pharmacovigilance (ISoP) Latin America (LATAM) Chapter (General Secertary of ISoP), Quito, Ecuador
| | - Angela Caro
- International Society of Pharmacovigilance, ISoP Secretariat Ltd, London, UK
- Pharmacy Career Director of Pontificia, Universidad Javeriana (President of ISoP), Bogotá, Colombia
| | - Helen Byomire Ndagije
- International Society of Pharmacovigilance (ISoP) Africa Chapter, Kampala, Uganda
- National Drug Authority, Directorate of Product Safety (President of ISoP Africa Chapter), Kampala, Uganda
| | - Ghita Benabdallah
- International Society of Pharmacovigilance (ISoP) Middle East Chapter, Rabat, Morocco
- Centre Anti Poison et de Pharmacovigilance du Maroc, Rabat WHO Collaborating Centre, Rabat, Morocco
| | - Houda Sefiani
- International Society of Pharmacovigilance (ISoP) Middle East Chapter, Rabat, Morocco
- Centre Anti Poison et de Pharmacovigilance du Maroc, Rabat WHO Collaborating Centre, Rabat, Morocco
| | - Hadir Rostom
- International Society of Pharmacovigilance (ISoP) Egypt Chapter, Cairo, Egypt
- Faculty of Pharmacy, MSA University (President of ISoP Egypt Chapter), 6th of October City, Giza, Egypt
| |
Collapse
|
3
|
Wang Y, Lin Y, Lin Q, Liang H, Cai W, Jiang D. Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database. Sci Rep 2023; 13:12257. [PMID: 37507539 PMCID: PMC10382477 DOI: 10.1038/s41598-023-39482-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2023] [Accepted: 07/26/2023] [Indexed: 07/30/2023] Open
Abstract
Rhabdomyolysis is a syndrome potentially fatal and has been associated with selective serotonin reuptake inhibitors (SSRIs) treatment in a few case reports. Herein, we purpose to establish the correlation between SSRIs use and rhabdomyolysis using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database. We conducted an analysis on reports that were submitted to the FAERS database during the period between January 1, 2004, and December 31, 2022. Four algorithms, including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayes geometric mean (EBGM), were employed to quantify the signals of rhabdomyolysis associated with SSRIs. In total, 16,011,277 non-duplicated reports were obtained and analyzed. Among 33,574 reports related to rhabdomyolysis, SSRIs were classified as primary suspected drug in 889 cases. Disproportionality analysis identified a positive signal between rhabdomyolysis and SSRIs (ROR: 2.86, 95% CI 2.67-3.05; PRR: 2.84, χ2: 1037.16; IC0.25 = 1.39; EBGM0.5 = 2.64). Among six SSRIs, fluvoxamine had the strongest signal (ROR: 11.64, 95% CI 8.00-16.93; PRR: 11.38, χ2: 265.51; IC0.25 = 2.41; EBGM0.5 = 8.31), whereas no significant signal of rhabdomyolysis was detected for paroxetine (ROR: 1.83, 95% CI 1.55-2.15; PRR: 1.82, χ2: 53.82; IC0.25 = 0.73; EBGM0.5 = 1.59). After excluding cases co-administered with statins, the signal of rhabdomyolysis associated with SSRIs remains significant. Our analysis reveals that there are differences in safety signals among six SSRIs in respect to the risk of rhabdomyolysis, with fluvoxamine displaying the highest risk signal, while paroxetine did not show a significant signal. Given the potentially lethal nature of rhabdomyolysis, healthcare professionals should inform patients of the potential risk of rhabdomyolysis associated with SSRIs prior to initiating treatment.
Collapse
Affiliation(s)
- Yan Wang
- Department of Pharmacy, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, China
| | - Yajing Lin
- Department of Pharmacy, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, China
| | - Qing Lin
- Department of Pharmacy, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, China
| | - Haiming Liang
- Department of Pharmacy, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, China
| | - Weiming Cai
- Department of Pharmacy, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, China.
| | - Dongbo Jiang
- Department of Pharmacy, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, China.
| |
Collapse
|
4
|
Abbas H, Zeitoun A, Watfa M, Karam R. Implementation of a Pharmacovigilance System in a Resources-Limited Country in the Context of COVID-19: Lebanon's Success Story. Ther Innov Regul Sci 2023; 57:178-185. [PMID: 36109433 PMCID: PMC9483279 DOI: 10.1007/s43441-022-00460-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2022] [Accepted: 09/01/2022] [Indexed: 11/25/2022]
Abstract
Implementation of Pharmacovigilance (PV) systems in resource-limited countries is a real challenge. The objective of this paper is to describe the implementation of an effective national PV system in Lebanon in the context of COVID-19, within a limited resources setting and with the absence of a guaranteed funding. In 2018, the PV center hosted at the Lebanese University, Faculty of Pharmacy under the supervision of the Quality Assurance of Pharmaceutical Products Program within the Lebanese Ministry of Public Health became an associate member of the World Health Organization (WHO) Program of International Drug Monitoring and recognized as Full member in 2021.This analysis highlights the requirements of the WHO that were met in Lebanon to create an effective PV system. The Lebanese experience shows that it is not only possible, but also crucial to implement a PV system in low to middle-income countries with limited resources and with the absence of a guaranteed funding in order to be able to promote patients' safety. Support from organizations like WHO and World Bank, skilled leadership, hard work and dedicated staff with efficient training, and finally mass awareness initiatives were all considered as key elements to implement a successful PV System. In the midst of a turbulent political, economic and health context, Lebanon has been able to develop one of the most active and rapidly evolving PV systems in the Middle East.
Collapse
Affiliation(s)
- Hanine Abbas
- Department of Chemistry and Biochemistry, Faculty of Science, Section 1, Lebanese University, Beirut, Lebanon
| | - Abeer Zeitoun
- Quality Assurance of Pharmaceutical Products Department, Lebanese Ministry of Public Health, Beirut, Lebanon
| | - Myriam Watfa
- Quality Assurance of Pharmaceutical Products Department, Lebanese Ministry of Public Health, Beirut, Lebanon
| | - Rita Karam
- Department of Chemistry and Biochemistry, Faculty of Science, Section 1, Lebanese University, Beirut, Lebanon. .,Quality Assurance of Pharmaceutical Products Department, Lebanese Ministry of Public Health, Beirut, Lebanon.
| |
Collapse
|
5
|
Stegmann JU, Jusot V, Menang O, Gardiner G, Vesce S, Volpe S, Ndalama A, Adou F, Ofori-Anyinam O, Oladehin O, Mendoza YG. Challenges and lessons learned from four years of planning and implementing pharmacovigilance enhancement in sub-Saharan Africa. BMC Public Health 2022; 22:1568. [PMID: 35978276 PMCID: PMC9383683 DOI: 10.1186/s12889-022-13867-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Accepted: 07/25/2022] [Indexed: 11/28/2022] Open
Abstract
Pharmacovigilance (PV) systems in many countries in sub-Saharan Africa (SSA) are not fully functional. The spontaneous adverse events (AE) reporting rate in SSA is lower than in any other region of the world, and healthcare professionals (HCPs) in SSA countries have limited awareness of AE surveillance and reporting procedures. The GSK PV enhancement pilot initiative, in collaboration with PATH and national PV stakeholders, aimed to strengthen passive safety surveillance through a training and mentoring program of HCPs in healthcare facilities in three SSA countries: Malawi, Côte d’Ivoire, and Democratic Republic of Congo (DRC). Project implementation was country-driven, led by the Ministry of Health via the national PV center or department, and was adapted to each country’s needs. The implementation phase for each country was scheduled to last 18 months. At project start, low AE reporting rates reflected that awareness of PV practices was very low among HCPs in all three countries, even if a national PV center already existed. Malawi did not have a functional PV system nor a national PV center prior to the start of the initiative. After 18 months of PV training and mentoring of HCPs, passive safety surveillance was enhanced significantly as shown by the increased number of AE reports: from 22 during 2000–2016 to 228 in 18 months to 511 in 30 months in Malawi, and ~ 80% of AE reports from trained healthcare facilities in Côte d’Ivoire. In DRC, project implementation ended after 7 months because of the SARS-CoV-2 pandemic. Main challenges encountered were delayed AE report transmission (1–2 months, due mainly to remoteness of healthcare facilities and complex procedures for transmitting reports to the national PV center), delayed or no causality assessment due to lack of expertise and/or funding, negative perceptions among HCPs toward AE reporting, and difficulties in engaging public health programs with the centralized AE reporting processes. This pilot project has enabled the countries to train more HCPs, increased reporting of AEs and identified KPIs that could be flexibly replicated in each country. Country ownership and empowerment is essential to sustain these improvements and build a stronger AE reporting culture.
Collapse
Affiliation(s)
| | | | | | - Gregory Gardiner
- GSK, London, UK.,Present affiliations: European Medicines Agency, Amsterdam, The Netherlands
| | - Sabino Vesce
- GSK, Nyon, Switzerland.,Present affiliations: Novartis, Basel, Switzerland
| | | | | | - Felix Adou
- Autorité Ivoirienne de Régulation Pharmaceutique (AIRP), Abidjan, Côte d'Ivoire
| | | | | | | |
Collapse
|
6
|
Rouamba T, Sondo P, Yerbanga IW, Compaore A, Traore‐Coulibaly M, Hien FS, Diande NA, Valea I, Tahita MC, Baiden R, Binka F, Tinto H. Prospective observational study to evaluate the clinical and biological safety profile of pyronaridine-artesunate in a rural health district in Burkina Faso. Pharmacol Res Perspect 2022; 10:e00987. [PMID: 35855566 PMCID: PMC9297024 DOI: 10.1002/prp2.987] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Accepted: 06/22/2022] [Indexed: 11/26/2022] Open
Abstract
The assessment in real-life conditions of the safety and efficacy of new antimalarial drugs is of greatest interest. This study aimed to monitor and evaluate both clinical and biological safety of pyronaridine-artesunate (PA) in real-life conditions in Burkina Faso's health system. This was a single-arm, open-label study, where patients attending Nanoro health facilities with uncomplicated malaria were consented to be part of a cohort event monitoring (CEM). At inclusion (day-0), PA was administered orally once a day for 3 days. Patients spontaneous reported any clinical adverse events (AEs) occurring within 28 days following the treatment. Additionally, the study focused on AEs of special interest (AESI), namely clinical signs related to hepatotoxicity and increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST). A nested subset of patients with blood sample collection at day-0 and day-7 were monitored to investigate the effect of PA on biochemistry parameters. From September 2017 to October 2018, 2786 patients were treated with PA. About 97.8% (2720/2786) of patients did not report any AE. The most commonly reported events were respiratory, thoracic, and mediastinal disorders (8.3 per 1000), infections and infestations (7.9 per 1000), and gastrointestinal disorders (7.2 per 1000). No clinical or biological hepatotoxicity event related to PA was reported during the follow-up. Changes in biochemistry parameters remained within laboratory reference ranges. The study showed that PA is a well-tolerated drug and should be considered as a good option by malaria control programs in countries where existing first-line antimalarial drugs are continuously threatened by the emergence of drug resistance.
Collapse
Affiliation(s)
- Toussaint Rouamba
- Clinical Research Unit of Nanoro, Institute for Research in Health SciencesNational Center for Scientific and Technological ResearchOuagadougouBurkina Faso
| | - Paul Sondo
- Clinical Research Unit of Nanoro, Institute for Research in Health SciencesNational Center for Scientific and Technological ResearchOuagadougouBurkina Faso
| | - Isidore W. Yerbanga
- Clinical Research Unit of Nanoro, Institute for Research in Health SciencesNational Center for Scientific and Technological ResearchOuagadougouBurkina Faso
| | - Adelaide Compaore
- Clinical Research Unit of Nanoro, Institute for Research in Health SciencesNational Center for Scientific and Technological ResearchOuagadougouBurkina Faso
| | - Maminata Traore‐Coulibaly
- Clinical Research Unit of Nanoro, Institute for Research in Health SciencesNational Center for Scientific and Technological ResearchOuagadougouBurkina Faso
| | - Franck S. Hien
- Clinical Research Unit of Nanoro, Institute for Research in Health SciencesNational Center for Scientific and Technological ResearchOuagadougouBurkina Faso
| | - Nassirou A. Diande
- Clinical Research Unit of Nanoro, Institute for Research in Health SciencesNational Center for Scientific and Technological ResearchOuagadougouBurkina Faso
| | - Innocent Valea
- Clinical Research Unit of Nanoro, Institute for Research in Health SciencesNational Center for Scientific and Technological ResearchOuagadougouBurkina Faso
| | - Marc Christian Tahita
- Clinical Research Unit of Nanoro, Institute for Research in Health SciencesNational Center for Scientific and Technological ResearchOuagadougouBurkina Faso
| | | | | | - Halidou Tinto
- Clinical Research Unit of Nanoro, Institute for Research in Health SciencesNational Center for Scientific and Technological ResearchOuagadougouBurkina Faso
| |
Collapse
|
7
|
Loomba AP. Pharmacovigilance in emerging economies: modeling interaction among barriers. JOURNAL OF ADVANCES IN MANAGEMENT RESEARCH 2022. [DOI: 10.1108/jamr-02-2022-0036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
PurposeThe main purpose of this paper is to identify and rank various barriers to pharmacovigilance (PV) in context of emerging economies and examine their interrelationships using the interpretive structural modeling (ISM) approach. The result is a model that offers insights about how to achieve rational and safe use of medicines and ensure patient safety as realized through robust national PV systems.Design/methodology/approachThe paper develops a model to analyze the interactions among PV barriers using the ISM approach. Based on input from clinical and medical product development experts, PV barriers in emerging economies were identified and reviewed. The hierarchical interrelationships among these PV barriers were analyzed in context of their driving/dependence powers.FindingsFindings of the study identify key PV barriers—lack of resources/infrastructure, weak legislation, unfair burden of disease, lack of PV capacity, training, and enforcement authority—that drive, or strongly influence, other barriers and thwart implementation of robust national PV systems in emerging economies. Pharmaceutical industry factors were PV barriers that were identified as autonomous, implying their relative disconnection from other barriers, and patient PV practices barrier was strongly dependent on other barriers.Research limitations/implicationsThe paper offers policy- and decision-makers alike with a framework to support further research into interdependencies among key PV barriers in emerging economies. It can serve as an impetus for further research with potential to broadening the understanding of how and why PV systems may be rendered ineffective. Future studies can be planned to apply the ISM approach to study PV barriers in the context of developed economies and draw lessons and implications for policy- and decision-makers by contrasting results from these studies.Practical implicationsThis paper contributes to the understanding of the multifaceted nature of PV and its barriers. The proposed approach gives public health decision-makers a better comprehension of driver PV barriers that have most influence on others versus dependent PV barriers, which are most influenced by others. Also, knowledge, attitude and practices of patients and caregivers can also be critical PV barriers in emerging economies. This information can be instrumental for public health policymakers, government entities, and health/PV practitioners to identify the PV barriers that they should prioritize for improvement and how to manage trade-offs between these barriers.Social implicationsPV barriers in emerging economies, as compared to developed economies, are inherently different and need to be examined in their specific context. The hierarchical ISM model suggests that resources and regulation initiatives by governments in emerging economies lead to through informed/enabled pharmaceutical supply chain players and eventually drive PV-specific knowledge, attitude, and practice outcomes improvements across their populace.Originality/valueThis paper highlights the deployment of ISM approach as a health policy decision support tool in the identifying and ranking barriers to effective PV systems in emerging economies, in terms of their contextual relationships, to achieve a better understanding as to how these interrelationships can affect national PV system outcomes.
Collapse
|
8
|
A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators. Ther Innov Regul Sci 2022; 56:717-743. [PMID: 35657484 PMCID: PMC9356965 DOI: 10.1007/s43441-022-00415-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2021] [Accepted: 04/28/2022] [Indexed: 11/10/2022]
Abstract
Background In the context of the growth of pharmacovigilance (PV) among developing countries, this systematic review aims to synthesise current research evaluating developing countries’ PV systems’ performance. Methods EMBASE, MEDLINE, CINAHL Plus and Web of Science were searched for peer-reviewed studies published in English between 2012 and 2021. Reference lists of included studies were screened. Included studies were quality assessed using Hawker et al.'s nine-item checklist; data were extracted using the WHO PV indicators checklist. Scores were assigned to each group of indicators and used to compare countries’ PV performance. Results Twenty-one unique studies from 51 countries were included. Of a total possible quality score of 36, most studies were rated medium (n = 7 studies) or high (n = 14 studies). Studies obtained an average score of 17.2 out of a possible 63 of the WHO PV indicators. PV system performance in all 51 countries was low (14.86/63; range: 0–26). Higher average scores were obtained in the ‘Core’ (9.27/27) compared to ‘Complementary’ (5.59/36) indicators. Overall performance for ‘Process’ and ‘Outcome’ indicators was lower than that of ‘Structural’. Conclusion This first systematic review of studies evaluating PV performance in developing countries provides an in-depth understanding of factors affecting PV system performance.
Supplementary Information The online version contains supplementary material available at 10.1007/s43441-022-00415-y.
Collapse
|
9
|
A qualitative exploration of pharmacovigilance policy implementation in Jordan, Oman, and Kuwait using Matland's ambiguity-conflict model. Global Health 2021; 17:97. [PMID: 34461946 PMCID: PMC8404321 DOI: 10.1186/s12992-021-00751-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Accepted: 08/10/2021] [Indexed: 11/29/2022] Open
Abstract
Background As Arab countries seek to implement the ‘Guideline on Good Pharmacovigilance Practice (GVP) for Arab countries’, understanding policy implementation mechanisms and the factors impacting it can inform best implementation practice. This study aimed to explore the mechanisms of and factors influencing pharmacovigilance policy implementation in Arab countries with more established pharmacovigilance systems (Jordan, Oman), to inform policy implementation in a country with a nascent pharmacovigilance system (Kuwait). Results Matland’s ambiguity-conflict model served to frame data analysis from 56 face-to-face interviews, which showed that policy ambiguity and conflict were low in Jordan and Oman, suggesting an “administrative implementation” pathway. In Kuwait, policy ambiguity was high while sentiments about policy conflict were varied, suggesting a mixture between “experimental implementation” and “symbolic implementation”. Factors reducing policy ambiguity in Jordan and Oman included: decision-makers’ guidance to implementors, stakeholder involvement in the policy’s development and implementation, training of policy implementors throughout the implementation process, clearly outlined policy goals and means, and presence of a strategic implementation plan with appropriate timelines as well as a monitoring mechanism. In contrast, policy ambiguity in Kuwait stemmed from the absence or lack of attention to these factors. Factors reducing policy conflict included: the policy’s compliance with internationally recognised standards and the policy’s fit with local capabilities (all three countries), decision-makers’ cooperation with and support of the national centre as well as stakeholders’ agreement on policy goals and means (Jordan and Oman) and adopting a stepwise approach to implementation (Jordan). Conclusions Using Matland’s model, both the mechanism of and factors impacting successful pharmacovigilance policy implementation were identified. This informed recommendations for best implementation practice in Arab as well as other countries with nascent pharmacovigilance systems, including increased managerial engagement and support, greater stakeholder involvement in policy development and implementation, and undertaking more detailed implementation planning.
Collapse
|
10
|
Oduor MA, Lotodo TC, Vik TA, Manyega KM, Loehrer P, Omondi AA, Oguda JO, Asirwa FC. Building a Sustainable Comprehensive Multiple Myeloma Program in Western Kenya. JCO Glob Oncol 2021; 7:400-407. [PMID: 33739854 PMCID: PMC8081545 DOI: 10.1200/go.20.00572] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Despite improved treatment strategies for multiple myeloma (MM), patient outcomes in low- and middle-income countries remain poor, unlike high-income countries. Scarcity of specialized human resources and diagnostic, treatment, and survivorship infrastructure are some of the barriers that patients with MM, clinicians, and policymakers have to overcome in the former setting. To improve outcomes of patients with MM in Western Kenya, the Academic Model Providing Access to Healthcare (AMPATH) MM Program was set up in 2012. In this article, the program's activities, challenges, and future plans are described distilling important lessons that can be replicated in similar settings. Through the program, training on diagnosis and treatment of MM was offered to healthcare professionals from 35 peripheral health facilities across Western Kenya in 2018 and 2019. Access to antimyeloma drugs including novel agents was secured, and pharmacovigilance systems were developed. Finally, patients were supported to obtain health insurance in addition to receiving peer support through participation in support group meetings. This article provides an implementation blueprint for similar initiatives aimed at increasing access to care for patients with MM in underserved areas.
Collapse
Affiliation(s)
| | | | - Terry A Vik
- Moi University, Eldoret, Kenya.,Indiana University School of Medicine, Indianapolis, IN
| | - Kelvin M Manyega
- AMPATH Oncology Institute, Eldoret, Kenya.,Directorate of Pharmacy & Nutrition, Moi Teaching & Referral Hospital, Eldoret, Kenya
| | | | | | - John O Oguda
- AMPATH Oncology Institute, Eldoret, Kenya.,Indiana University School of Medicine, Indianapolis, IN
| | | |
Collapse
|
11
|
Shuleta Qehaja S, Sterjev Z, Shuturkova L, Kapedanovska A, Naumovska Z, Krasniqi V, Elezi E. Knowledge, attitude and practice of pharmacists to pharmacovigilance and adverse drug reactions reporting process: a cross-sectional study in Kosovo. MAKEDONSKO FARMACEVTSKI BILTEN 2021. [DOI: 10.33320/10.33320/maced.pharm.bull.2021.67.01.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Pharmacovigilance (PV) and drug safety monitoring have an essential role in protecting public health. A cross-sectional study evaluated pharmacist knowledge, attitude and practice toward PV and adverse drug reactions (ADRs) reporting. The structured validated questionnaire was distributed to 550 randomly selected pharmacists in the whole Kosovo region. 405 out of 550 pharmacists responded to the questionnaire. Most pharmacists have insufficient knowledge about pharmacovigilance and the ADRs reporting process. The main reasons for under-reporting were little knowledge of pharmacovigilance and adverse reporting process, lack of time, and lack of infrastructure. However, pharmacists showed a positive attitude and stated that they would practice pharmacovigilance if they receive the training. There is a necessity to intensify communication among all stakeholders involved in PV. In addition, continuous training and education are needed to increase pharmacist's awareness and knowledge of PV and their participation in the ADRs reporting process.
Keywords: Pharmacovigilance, adverse drug reaction, knowledge, attitude, practice, pharmacists, Kosovo
Collapse
Affiliation(s)
- Selvete Shuleta Qehaja
- Alma Mater Europaea Campus College "Rezonanca", Glloku te Shelgjet "Veternik", 10000 Prishtina, Kosovo
| | - Zoran Sterjev
- Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy, Majka Tereza 47, 1000 Skopje, North Macedonia
| | - Ljubica Shuturkova
- Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy, Majka Tereza 47, 1000 Skopje, North Macedonia
| | - Aleksandra Kapedanovska
- Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy, Majka Tereza 47, 1000 Skopje, North Macedonia
| | - Zorica Naumovska
- Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy, Majka Tereza 47, 1000 Skopje, North Macedonia
| | - Virtyte Krasniqi
- Kosovo Medicines Agency, Rrethi i spitalit (QKUK), 10000 Prishtina, Kosovo
| | - Erblin Elezi
- Central Pharmacy - University Clinical Center, 10000 Prishtina, Kosovo
| |
Collapse
|
12
|
Adedeji-Adenola H, Nlooto M. Direct reporting of adverse drug reactions by healthcare consumers in Africa: a narrative review. Int J Clin Pharm 2020; 43:11-24. [PMID: 32902780 DOI: 10.1007/s11096-020-01141-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Accepted: 08/29/2020] [Indexed: 11/30/2022]
Abstract
Background The challenges of under-reporting of adverse drug reactions have been identified as a major setback for the pharmacovigilance system worldwide. Direct reporting by health care consumers has been adopted in some developed and developing countries with a positive impact in improving pharmacovigilance activities through increased reporting rate. There are limited reports on direct reporting and its outcome in Africa. Aim of the review The study aimed to identify and present the available evidence on direct reporting of adverse drug reactions by healthcare consumers in Africa. Methods A review guided by Cochrane handbook was conducted. Electronic scientific databases such as PubMed, Cumulative Index to Nursing and Allied Health Literature, Embase and Cochrane Library were searched. Google scholar, general Google search engine, the website for the regulatory resources for Africa and World Health Organisation-Uppsala Monitoring were also searched for available guidelines, documents and publications. The review period was January 1992 to October 2019. The results were analysed descriptively. Results This study identified 16 African countries that have included healthcare consumers as eligible to report adverse drug reactions in their policy/guidelines. There is low awareness of healthcare consumers on pharmacovigilance system. Eight (8) out of thirty-six (36) African countries that are members of the World Health Organisation Programme for International Drug Monitoring have formally launched direct reporting by healthcare consumers which are 14.2% of African countries. There is a wide range of difference between the rate of adverse drug reactions report submitted by health care consumers as compared with healthcare workers. Paper form, text messages, telephone and web application-based reporting system have been used by different countries that have launched direct reporting. Poor infrastructure, low awareness and lack of a reporting culture are major challenges while the availability of common reporting methods is a potential opportunity of promoting direct reporting in African countries. Conclusions Few African countries have adopted and launched direct reporting. Reporting rate through direct methods is still relatively low when compared with reporting by healthcare workers. Published legal framework, policies, guidelines and studies on direct reporting are limited. Availability of a system and reporting method are opportunities to improve and overcome probable challenges.
Collapse
Affiliation(s)
- Halimat Adedeji-Adenola
- Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, Durban, 4000, South Africa.
| | - Manimbulu Nlooto
- Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, Durban, 4000, South Africa.,Department of Pharmacy, University of Limpopo, Polokwane, South Africa
| |
Collapse
|
13
|
Andrade PHS, de Almeida ACB, Dos Santos AKS, Lobo IMF, da Silva FA, da Silva WB. Challenges to the consolidation of pharmacovigilance practices in Brazil: limitations of the hospital pharmacist. Ther Adv Drug Saf 2020; 11:2042098620933748. [PMID: 32864089 PMCID: PMC7430076 DOI: 10.1177/2042098620933748] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2020] [Accepted: 05/11/2020] [Indexed: 11/16/2022] Open
Abstract
Aims: The aim of this study was to present the needs of hospital pharmacists in pharmacovigilance practices. Methods: This study has a cross-sectional design and was carried out with hospital pharmacists in Brazil. The sample was obtained by voluntary recruitment. Pharmacists who worked at Brazilian hospitals and were registered in their respective regulatory councils were invited to participate in the present study. A personalized questionnaire was developed by the authors and was electronically filled out by the respondents on the platform ‘Google forms’. The questionnaire was nationally available on the digital platform of the Pharmacy Federal Council, the Brazilian Society of Hospital Pharmacy and Health Services, four Pharmacy regional councils and the social network farmacêuticoclínico®. Quantitative variables were analyzed by mean and standard deviation. The qualitative variables were analyzed by means of absolute and relative frequency. Difficulties related to pharmacovigilance activities are presented in an Ishikawa diagram in the Supplemental Material online. Results: Of the 27 federative units of Brazil, we obtained answers from pharmacists located in 85.2% (n = 23) of them. Among the pharmacovigilance practices developed by Brazilian pharmacists, the adverse drug reaction investigation (55.4%) and notification activities (47.0%) were worthy of note. Numerous difficulties were reported by the pharmacists, highlighting the difficulty in monitoring the medication and imputation of causality (27.7%). After categorizing the difficulties reported, it was observed that the category ‘people involved’ (45.1%) stood out from the others. Conclusion: This study pointed out numerous challenges to pharmacovigilance practices involving pharmacists in Brazil. It is believed that the correction of certain difficulties may impact on the better consolidation of pharmacovigilance activities in the country. However, regulatory agencies at all hierarchical levels of pharmacovigilance must work together to make it possible. Plain language Summary Challenges to the consolidation of pharmacovigilance This is a study that seeks to present the needs of Brazilian hospital pharmacists in relation to pharmacovigilance activities. Through online interviews, pharmacists answered a questionnaire, presented the pharmacovigilance activities they develop and expressed their anxieties and difficulties for the development of these activities. With this study, it was concluded that numerous activities of active search, investigation and notification of adverse drug reaction are developed by Brazilian pharmacists. However, each pharmacist performs a different method of pharmacovigilance. In addition, it was observed that among the interviewees there was a perception of insufficient professional training and a shortage of professionals to assist in pharmacovigilance activities. These were the main difficulties reported. Therefore, the search for models or agile solutions to solve problems involving adverse drug reactions seems necessary for a better consolidation of pharmacovigilance services in Brazil.
Collapse
Affiliation(s)
- Paulo Henrique Santos Andrade
- Departamento de Farmácia, Universidade Federal de Sergipe, Núcleo de Pesquisa em Produtos Naturais e Assistência Farmacêutica (NUPPNAF), Av. Marechal Rondon, S/n - Jardim Rosa Elze, São Cristóvão, SE 49100-000, Brazil
| | | | | | - Iza Maria Fraga Lobo
- University Hospital of Sergipe, Federal University of Sergipe, Aracaju, Sergipe, Brazil
| | - Francilene Amaral da Silva
- Nucleus of Research in Natural Products and Pharmaceutical Care, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil
| | - Wellington Barros da Silva
- Nucleus of Research in Natural Products and Pharmaceutical Care, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil
| |
Collapse
|
14
|
Shrestha S, Palaian S. Respiratory concerns of gabapentin and pregabalin: What does it mean to the pharmacovigilance systems in developing countries? F1000Res 2020; 9:32. [PMID: 33728039 PMCID: PMC7919607 DOI: 10.12688/f1000research.21962.1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/22/2021] [Indexed: 10/29/2023] Open
Abstract
Gabapentin and pregabalin, commonly known as gabapentinoids, have been widely used globally. This paper highlights the serious breathing problems due to using gabapentin and pregabalin which was warned by the United States Food and Drug Administration on December, 2019. In this article, we tried to recommend suggestions for controlling these adverse drug reactions (ADRs). Safety reports of gabapentin and pregabalin should be obtained from concerned manufacturers and reviewed for respiratory depression effects. There should be strict prescription monitoring and drug use evaluation studies. Concurrent use of gabapentin and pregabalin with other respiratory depressants such as opioids should be strictly monitored. Educating patients can help in the early detection of ADRs due to gabapentin and pregabalin. Anecdotal reports on these medications should be encouraged.
Collapse
Affiliation(s)
- Sunil Shrestha
- Department of Pharmacy, Nepal Cancer Hospital and Research Center, Lalitpur, Nepal
- Department of Pharmaceutical and Health Service Research, Nepal Health Research and Innovation Foundation, Lalitpur, Nepal
| | - Subish Palaian
- Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates
| |
Collapse
|
15
|
Shrestha S, Palaian S. Respiratory concerns of gabapentin and pregabalin: What does it mean to the pharmacovigilance systems in developing countries? F1000Res 2020; 9:32. [PMID: 33728039 PMCID: PMC7919607 DOI: 10.12688/f1000research.21962.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/22/2021] [Indexed: 11/20/2022] Open
Abstract
Gabapentin and pregabalin, commonly known as gabapentinoids, have been widely used globally. This paper highlights the serious breathing problems due to using gabapentin and pregabalin which was warned by the United States Food and Drug Administration on December, 2019. In this article, we tried to recommend suggestions for controlling these adverse drug reactions (ADRs). Safety reports of gabapentin and pregabalin should be obtained from concerned manufacturers and reviewed for respiratory depression effects. There should be strict prescription monitoring and drug use evaluation studies. Concurrent use of gabapentin and pregabalin with other respiratory depressants such as opioids should be strictly monitored. Educating patients can help in the early detection of ADRs due to gabapentin and pregabalin. Anecdotal reports on these medications should be encouraged.
Collapse
Affiliation(s)
- Sunil Shrestha
- Department of Pharmacy, Nepal Cancer Hospital and Research Center, Lalitpur, Nepal.,Department of Pharmaceutical and Health Service Research, Nepal Health Research and Innovation Foundation, Lalitpur, Nepal
| | - Subish Palaian
- Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates
| |
Collapse
|
16
|
Drummond PLDM, Santos RMMD, Silva CDA, Pádua CAMD. Pharmacovigilance of thalidomide in the Brazilian Health System and patient safety. BRAZ J PHARM SCI 2020. [DOI: 10.1590/s2175-97902020000318726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
17
|
Ingle S, Bansod K, Bashir MM. Adverse drug reaction profile in Amravati region of India: A pharmacovigilance study. J Pharm Bioallied Sci 2020; 12:155-162. [PMID: 32742114 PMCID: PMC7373106 DOI: 10.4103/jpbs.jpbs_226_19] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2019] [Revised: 12/15/2019] [Accepted: 12/24/2020] [Indexed: 11/20/2022] Open
Abstract
Background: This pharmacovigilance study was conducted in Amravati region of central India to identify the nature and prevalence of adverse drug reactions, which will be helpful for better drug prescription practice and management of diseases. Materials and Methods: Adverse drug reaction reporting forms from April 2016 to March 2019, were collected from the pharmacovigilance center, which include details of demographics, investigations, concomitant drug history, and details of present complaints including reaction details, onset, recovery, drug information, hospitalization, management, and assessment. Results: A total of 19 cases were reported. Approximately 47.4% male and 52.6% female experienced the reactions with age-group ranging from 15 to 75 years. The most common adverse drug reactions were caused by antimicrobial agents (47.6%) followed by other group of drugs (37%) and nonsteroidal anti-inflammatory drugs (15.9%). Polypharmacy was the most common cause (31.6%) with the most common route being intravenous (42.1%). Skin reactions were the most common (84.2%). Antitubercular drugs were more commonly responsible for exfoliative lesions, whereas paracetamol and unknown drugs were responsible for multiple ulcerative lesions. Reactions to antitubercular drugs were considered as possible (15.8%), whereas with other drugs (63.2%), it was probable. Conclusion: It is a tip of the iceberg, which provides important demographic details in which adverse drug reactions were reported. Cutaneous reactions due to common drugs are responsible for hospitalization of the patients. There is an urgent need of training for health-care providers so that reporting can be improved and better picture can emerge.
Collapse
|
18
|
Nzolo D, Kuemmerle A, Lula Y, Ntamabyaliro N, Engo A, Mvete B, Liwono J, Lusakibanza M, Mesia G, Burri C, Mampunza S, Tona G. Development of a pharmacovigilance system in a resource-limited country: the experience of the Democratic Republic of Congo. Ther Adv Drug Saf 2019; 10:2042098619864853. [PMID: 31360433 PMCID: PMC6637826 DOI: 10.1177/2042098619864853] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2019] [Accepted: 06/19/2019] [Indexed: 11/24/2022] Open
Abstract
Implementation of pharmacovigilance (PV) systems in resource-limited countries is a real endeavor. Despite country- and continent-specific challenges, the Democratic Republic of the Congo (DRC) has been able to develop one of the most active PV systems in the sub-Saharan Africa. The World Health Organization (WHO) regional Office identified the DRC experience to set up a PV system for antimalarial drugs safety monitoring as a ‘best practice’ that needed to be documented in order to help DRC improve its PV system and to be scaled up in other African countries. In response to the WHO request, a best practices and bottlenecks analysis was conducted in 2015. This analysis was updated in 2018 in the light of the minimum requirements of the WHO to set up a PV system taking into account other guidance for PV systems. The following themes were retained for analysis: (1) creation of the national PV center; (2) implementation of PV in the health system; (3) data collection and analysis; (4) collaboration with public health programs; (5) collaboration with the National Regulatory Authority. Lessons learnt from the DRC experience show that it is possible to implement PV systems in order to promote patients’ safety in resource limited sub-Saharan African countries with no guaranteed funding. The ability of national PV centers to collaborate with Public health stakeholders, including public health authorities at all levels as well as public health programs, and to use existing health information systems are considered the main key to success and may substantially reduce the cost of PV activities.
Collapse
Affiliation(s)
- Didier Nzolo
- Unit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, 11, Democratic Republic of Congo
| | | | - Yves Lula
- Unit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| | - Nsengi Ntamabyaliro
- Unit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| | - Aline Engo
- Unit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| | - Bibiche Mvete
- Unit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| | - Jerry Liwono
- Unit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| | - Mariano Lusakibanza
- Unit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| | - Gauthier Mesia
- Unit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| | - Christian Burri
- Swiss Tropical and Public Health Institute, Basel, Switzerland
| | - Samuel Mampunza
- Unit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| | - Gaston Tona
- Unit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| |
Collapse
|
19
|
Adisa R, Adeniyi OR, Fakeye TO. Knowledge, awareness, perception and reporting of experienced adverse drug reactions among outpatients in Nigeria. Int J Clin Pharm 2019; 41:1062-1073. [PMID: 31140162 DOI: 10.1007/s11096-019-00849-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2019] [Accepted: 05/17/2019] [Indexed: 10/26/2022]
Abstract
Background Higher incidence of adverse drug reactions (ADRs) remain a major cause of morbidity and mortality. Most targeted ADR reporting activities are mainly professional-centered with less attention to patients' knowledge, perception and selfreporting of experienced ADRs. Objectives To comprehensively evaluate patients' knowledge, awareness, perception and reporting of experienced ADRs. Setting Three public healthcare facilities in Ibadan, southwestern Nigeria. Method A questionnaire-guided cross-sectional interview of 1190 consented ambulatory adult patients consecutively recruited from various clinics of the selected hospitals between February and June 2018. The 32-item pretested questionnaire comprised open- and closed-ended questions, as well as open-ended questions with relevant prompts. Data were summarised using descriptive statistics, while Chi square was used to investigate association between relevant categorical variables at p < 0.05. Main outcome measure Knowledge, awareness, perception and reporting of experienced ADRs among patients. Results Response rate was 99.1%. Mean age was 40.6 ± 14.9 years. Forty-nine (4.1%) patients were aware of pharmacovigilance. A total of 964 (81.0%) correctly understood what can be regarded as serious adverse drug reactions (ADRs), 444 (37.3%) had previously experienced ADRs, while 77 (6.5%) experienced reactions with current medication(s). Of this, 64 (83.1%) made a report largely to physician (52; 81.3%). Summarily, reported reactions were more with antimalarials (214; 49.1%), with itching (168; 78.5%) constituting the most frequently occurring reaction. Use of text message (276; 27.2%) and filling of ADR report form (248; 24.4%) were topmost on the list of suggested methods for ADR reporting. There was a significant association between patient's age and awareness of pharmacovigilance (p = 0.015), while educational qualification (p = 0.001) significantly influenced tendency to make a report of experienced ADRs. Conclusion Approximately four percent of patients were aware of pharmacovigilance, while more than three-quarters correctly understood the concept of serious adverse drug reactions. A little above one-quarter had previously experienced one form of reaction or the other, with majority reporting such reactions to physician. Continuous education of stakeholders in pharmacovigilance activities is advocated, while patient's active involvement in spontaneous reporting of ADRs should be carefully considered.
Collapse
Affiliation(s)
- Rasaq Adisa
- Department of Clinical Pharmacy and Pharmacy Administration, University of Ibadan, Ibadan, Nigeria.
| | - Omotola Rukayat Adeniyi
- Department of Clinical Pharmacy and Pharmacy Administration, University of Ibadan, Ibadan, Nigeria
| | - Titilayo Oyelola Fakeye
- Department of Clinical Pharmacy and Pharmacy Administration, University of Ibadan, Ibadan, Nigeria
| |
Collapse
|
20
|
Varallo FR, Forgerini M, Herdeiro MT, de Carvalho Mastroianni P. Harmonization of Pharmacovigilance Regulation in Brazil: Opportunities to Improve Risk Communication. Clin Ther 2019; 41:598-603. [PMID: 30792075 DOI: 10.1016/j.clinthera.2019.01.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2018] [Revised: 01/14/2019] [Accepted: 01/19/2019] [Indexed: 11/18/2022]
Abstract
Brazilian pharmacovigilance regulations involve 3 spheres: health services, Marketing Authorization Holders (MAHs), and sanitary agency. Drug tolerability began to be effectively assessed in Brazil after the founding of the National Agency of Sanitary Surveillance, which developed the Sentinel Network Project. The objective of the Sentinel Network Project is to increase the adverse drug reaction (ADR) reporting rate by health care professionals in the hospital setting. Pharmacovigilance practices became mandatory for MAHs, and patient tolerability issues were considered in drug policy in Brazil only as recently as 2000. However, despite recent events, the regulatory advancements in pharmacovigilance in Brazil are only equivalent to international practices (ie, those of the European Union). The pharmacovigilance system in the European Union integrates the national authorities, the European Commission, and the European Medicines Agency, which is responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use in the European Union. Furthermore, ADR patient reporting is included in the new EU pharmacovigilance regulations. Numerous possible ways are available to improve the Brazilian pharmacovigilance system, mainly through regulations of biosimilar, nanotechnology, and veterinary medicines or by training health care professionals and patients to report nonserious cases and quality deviations. It is necessary to encourage and develop strategies for decentralizing pharmacovigilance actions in the whole country, as is common practice in several EU countries. Motivating and considering ADR reports by patients and improving feedback and audit practices in health care services and MAHs are also necessary measures. With the inclusion of Brazil as a member of the International Conference of Harmonization, significant changes in pharmacovigilance regulation are expected; these updates, which will consider international standards, will improve signal detection and risk communication.
Collapse
Affiliation(s)
| | - Marcela Forgerini
- Department of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University, Araraquara, Brazil
| | - Maria Teresa Herdeiro
- Institute of Biomedicine - iBiMED, Department of Medical Sciences, University of Aveiro, Aveiro, Portugal
| | | |
Collapse
|
21
|
|
22
|
Glamočlija U, Tubić B, Kondža M, Zolak A, Grubiša N. Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study. Croat Med J 2018; 59:124-131. [PMID: 29972735 PMCID: PMC6045893 DOI: 10.3325/cmj.2018.59.124] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Aim To compare individual case safety reports (ICSR) rates and characteristics between Croatia, Serbia, Montenegro, and Bosnia and Herzegovina (B&H). Methods This retrospective pharmacoepidemiological study used the data from ICSR received by the Agency for Medicines and Medical Devices in B&H in 2011-2016. The number, characteristics, and sources of reports, suspected drugs, and patient characteristics were analyzed. The results were compared with the publicly available data from Croatia, Serbia, and Montenegro. Results The number of reported adverse drug reactions per one million of inhabitants was lowest in B&H and highest in Croatia. There were significant differences in reporter characteristics, sources of reports, and the percentage of missing data in ICSR, while the Anatomical Therapeutic Chemical product classes, patient’s sex, and adverse drug reaction System Organ Classes were similar. Conclusion Despite the historical and geographical vicinity of B&H and its neighboring countries, there were significant differences in indicators of pharmacovigilance development.
Collapse
Affiliation(s)
- Una Glamočlija
- Una Glamočlija, School of Medicine, University of Mostar, Bijeli brijeg bb, 88 000 Mostar, Bosnia and Herzegovina,
| | | | | | | | | |
Collapse
|